Studied for anxiolytic pathways without classic benzodiazepine sedation.
Target condition: glp1 agonists. Body system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..
Logic chain
selank studied for anxiolytic pathways without classic benzodiazepine sedation..
glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.
If selank reaches the affected tissue, it may shift the repair/breakdown balance.
This chain is tested in animal or lab models only.
Parent peptide claims relevant here
In a 2008 randomized study of 62 patients with GAD and neurasthenia, Selank showed anxiolytic efficacy comparable to medazepam on psychometric scales without reported sedation, cognitive impairment, tolerance or withdrawal.
Selank administration in rats alters expression of 45 neurotransmission-related genes at 1 hour and 22 genes at 3 hours, with positive correlation to GABA effects.
Commercial vendors and clinics market this compound (7 commercial/clinic sources catalogued) — marketing material, not evidence.
2017 study showing Selank's anxiolytic effects comparable to benzodiazepines in rat stress model.
2019 rat study on Selank protecting against alcohol-related memory issues via BDNF regulation.
Evidence tier
Preclinical — animal and in vitro studies only. No published human trials for this specific combination.
What we do not know
Whether selank reaches glp1 agonists tissue at functional concentrations
Optimal dosing, route, and duration for this target
Interaction with standard-of-care treatments for glp1 agonists
Long-term safety profile in this population
Safety note
All peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound.
the whole object this page is drawn from, as JSON
{
"schema":"https://miscsubjects.com/schemas/jarticle.json",
"status":"published",
"slug":"selank-glp1-agonists",
"title":"Selank × GLP-1 agonists (class)",
"kind":"standard",
"summary":"glp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits. Studied for anxiolytic pathways without classic",
"created":"2026-08-08T04:22:48.407Z",
"body": [
"## Regeneration vs degeneration — where this fits\n\nglp1 agonists represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits.\n\n## What is known\n\nStudied for anxiolytic pathways without classic benzodiazepine sedation.\n\nTarget condition: glp1 agonists.\nBody system: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss..\n\n## Logic chain\n\n1. selank studied for anxiolytic pathways without classic benzodiazepine sedation..\n2. glp1 agonists involves metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. dysfunction.\n3. If selank reaches the affected tissue, it may shift the repair/breakdown balance.\n4. This chain is tested in animal or lab models only.\n\n## Parent peptide claims relevant here\n\n- In a 2008 randomized study of 62 patients with GAD and neurasthenia, Selank showed anxiolytic efficacy comparable to medazepam on psychometric scales without reported sedation, cognitive impairment, tolerance or withdrawal.\n- Selank administration in rats alters expression of 45 neurotransmission-related genes at 1 hour and 22 genes at 3 hours, with positive correlation to GABA effects.\n- Commercial vendors and clinics market this compound (7 commercial/clinic sources catalogued) — marketing material, not evidence.\n- 2017 study showing Selank's anxiolytic effects comparable to benzodiazepines in rat stress model.\n- 2019 rat study on Selank protecting against alcohol-related memory issues via BDNF regulation.\n\n## Evidence tier\n\nPreclinical — animal and in vitro studies only. No published human trials for this specific combination.\n\n## What we do not know\n\n- Whether selank reaches glp1 agonists tissue at functional concentrations\n- Optimal dosing, route, and duration for this target\n- Interaction with standard-of-care treatments for glp1 agonists\n- Long-term safety profile in this population\n\n## Safety note\n\nAll peptide use for glp1 agonists is research-context only. Not medical advice. Consult a physician before any experimental compound."
],
"facts": {
"converted_from":"markdown",
"original_updated":"2026-07-17T02:41:37.472Z",
"register":"standard",
"category":null
},
"model":"grok/grok-4.3",
"tags": [
"peptide"
],
"type":"article",
"updated":"2026-10-08T11:31:17.149Z",
"version":1,
"hash":"741eb8e1c7cc01706544b717e1eb53b19e9a11dbd8152bbf838f1e580f4a68c5",
"styling": {
"scope":"shared",
"how":"no value on the page is set by hand: each comes from this theme, and each theme value becomes the CSS variable named beside it. PATCH https://miscsubjects.com/api/jarticles/theme changes them.",
"widget_style": {
"what":"every widget may carry style: {…}; these are the only keys it reads",
"rotate":"degrees, a number",
"offset_x":"pixels, a number",
"offset_y":"pixels, a number",
"pulse":"true to pulse"
},
"theme": {
"color": {
"page_bg":"#f5f5f7",
"sheet_bg":"#ffffff",
"ink":"#1d1d1f",
"soft":"#424245",
"muted":"#6e6e73",
"dim":"#86868b",
"line":"#d2d2d7",
"accent":"#0071e3",
"accent_soft":"rgba(0,113,227,0.08)",
"link":"#0066cc",
"selection":"rgba(0,113,227,0.18)",
"widget_bg":"#f5f5f7",
"widget_border":"#d2d2d7",
"card_bg":"#ffffff",
"code_bg":"#f5f5f7",
"json_bg":"#161b19",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#928d7e",
"json_punct":"#6b6759",
"json_bar":"#0e1512",
"kind_badge_bg":"#0e6e60",
"kind_badge_ink":"#ffffff"
},
"color_dark": {
"page_bg":"#000000",
"sheet_bg":"#1d1d1f",
"ink":"#f5f5f7",
"soft":"#d2d2d7",
"muted":"#a1a1a6",
"dim":"#86868b",
"line":"#424245",
"accent":"#2997ff",
"accent_soft":"rgba(41,151,255,0.12)",
"link":"#2997ff",
"selection":"rgba(41,151,255,0.25)",
"widget_bg":"#2c2c2e",
"widget_border":"#424245",
"card_bg":"#1d1d1f",
"code_bg":"#2c2c2e",
"json_bg":"#0a0d0c",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#757062",
"json_punct":"#5d665f",
"json_bar":"#060807",
"kind_badge_bg":"#4fc1ab",
"kind_badge_ink":"#0b0f0d"
},
"font": {
"display":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"body":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"mono":"ui-monospace,SFMono-Regular,\"SF Mono\",Menlo,Consolas,monospace",
"google_fonts":""
},
"size": {
"body":"17px",
"small":"17px",
"eye":"17px",
"lead":"17px",
"h1":"52px",
"h2":"34px",
"h3":"22px",
"byline":"17px",
"h1_measure":"none",
"code":"17px",
"json":"17px",
"widget_title":"17px"
},
"leading": {
"body":"1.7",
"head":"1.18",
"lead":"1.5",
"json":"1.6"
},
"weight": {
"display":"700",
"head":"700",
"body":"400",
"strong":"700",
"eye":"700"
},
"tracking": {
"eye":"0.14em",
"display":"-0.03em",
"body":"-0.006em",
"badge":"0.08em"
},
"layout": {
"sheet_width":"1000px",
"text_width":"880px",
"gutter":"16px",
"sheet_padding":"56px 64px 64px",
"sheet_padding_mobile":"24px 18px 40px",
"sheet_margin":"28px auto 72px",
"block_gap":"1.15em",
"widget_gap":"28px",
"grid_gap":"14px"
},
"border": {
"sheet":"0px solid",
"sheet_radius":"30px",
"widget":"1px solid",
"widget_radius":"24px",
"card_radius":"24px",
"badge_radius":"999px",
"rule":"1px solid",
"code_radius":"18px",
"accent_bar":"3px"
},
"shadow": {
"sheet":"0 1px 1px rgba(0,0,0,.02),0 6px 26px rgba(0,0,0,.05)",
"widget":"none",
"card_hover":"0 10px 28px -16px rgba(28,27,23,0.35)"
},
"motion": {
"hover":"160ms ease"
}
}
},
"page":"https://miscsubjects.com/a/selank-glp1-agonists",
"json":"https://miscsubjects.com/a/selank-glp1-agonists.json",
"markdown":"https://miscsubjects.com/a/selank-glp1-agonists.md",
"theme":"https://miscsubjects.com/article-theme.json",
"calls": [
{
"what":"this article as a page (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/selank-glp1-agonists",
"headers": {}
},
{
"what":"this article as its object (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/selank-glp1-agonists.json",
"headers": {}
},
{
"what":"this article as Markdown (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/selank-glp1-agonists.md",
"headers": {}
},
{
"what":"the object with its hash, drafts too",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/selank-glp1-agonists",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"one piece and that piece’s hash",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/selank-glp1-agonists/at?path=facts",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"grep: every key or value that matches, with the path to change it",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/selank-glp1-agonists/grep?q=owner",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"change pieces (set, merge, delete, append, insert, move); if-match is the hash",
"method":"PATCH",
"url":"https://miscsubjects.com/api/jarticles/selank-glp1-agonists",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash from the read>"
},
"body": {
"ops": [
{
"op":"set",
"path":"facts.example",
"value":1
}
]
}
},
{
"what":"replace the whole object",
"method":"PUT",
"url":"https://miscsubjects.com/api/jarticles/selank-glp1-agonists",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash>"
},
"body": {
"slug":"selank-glp1-agonists",
"title":"…"
}
},
{
"what":"fetch every source, hash what came back and check the quote is in it",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/selank-glp1-agonists/verify",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {}
},
{
"what":"an Obsidian-style command",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/cli",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {
"command":"backlinks",
"file":"selank-glp1-agonists"
}
}
]
}